Group 1 - The core viewpoint of the news highlights the significant growth potential in the global GLP-1 drug market, which is currently dominated by Novo Nordisk and Eli Lilly, with other multinational corporations (MNCs) accelerating their involvement [1][2] - The stock price of Paig BioPharma-B (02565) has increased over 5% recently, with a cumulative increase of more than 3.1 times since its listing, indicating strong market interest and performance [1] - Zhejiang Securities emphasizes that the GLP-1 sector has substantial room for growth in terms of potential patient base and market size, making it a critical area for MNCs in the metabolic disease field [1] Group 2 - PB-718, a key product of Paig BioPharma, is a novel long-acting GLP-1/GCG dual receptor agonist targeting MASH treatment, showing promising clinical results [2] - The clinical trial results for PB-718 indicate a significant reduction in liver fat content, with a mean percentage change of -57.14% after 18 weeks of treatment at a dosage of 1.6mg, outperforming Semaglutide in a shorter treatment duration [2]
港股异动 | 派格生物医药-B(02565)午前涨超5% GLP-1多靶点领域临床进度靠前 PB-718为公司旗下重磅品种